Merck & Co Inc (MRK) Heads Down For the 2nd Day In A Row, in an Uptrend Over Past 30 Days; Nears 20 Day Moving Average

Merck & Co Inc Daily Price Recap

Merck & Co Inc closed the previous day down 0.51% ($0.41); this denotes the 2nd day in a row it has gone down. The change in price came along side change in volume that was down 32.5% from previous day, but up 17.18% from the Wednesday of last week. The daily price chart of Merck & Co Inc below illustrates.

Merck & Co Inc Technical Analysis

The first thing we should note is that the current price of Merck & Co Inc is sitting close to its 20 day moving averages; moving average crosses often indicate a change in momentum, so this may be worth keeping an eye on. Volatility for Merck & Co Inc has been contracting over the past two weeks relative to volatility over the past month. Whether volatility reverts will be something to watch. Trend traders will want to observe that the strongest trend appears on the 30 day horizon; over that time period, price has been moving up. For additional context, note that price has gone up 8 out of the past 14 days.

Overheard Around the Web

Over on StockTwits, here’s an example of what they’re saying about MRK:

    $IFRX So Merck & Co. $MRK you want to buy us now or wait until we are at $50?

    Entered into a clinical collaboration agreement with Merck & Co, Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada) to evaluate the combination of IFX-1 and Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab) in patients with an undisclosed tumor type. Under the terms of the agreement, InflaRx will conduct a Phase IIa clinical study with two IFX-1 arms, including one with KEYTRUDA®. KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., Whitehouse Station, New Jersey, U.S.A, a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

    https://www.inflarx.de/Home/Investors/Press-Releases/04-2020-InflaRx-Reports-Full-Year-2019-Financial—Operating-Results.html